Tauriga Sciences, Inc., a revenue generating company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, announced that it has entered into a $5,000,000 financing agreement with the Tangiers Global, LLC (“Tangiers”) investment fund (“Equity Line” or “Facility”). The $5,000,000 financing is in the form of an Equity Line of Credit over a maximum duration of 36 months (the “Term”).

Tauriga’s Chief Executive Officer, Seth M. Shaw, expressed: "This funding facility provides the Company with a viable long-term platform to both grow its existing operations as well as develop other business activities under current consideration, including the potential pharmaceutical grade version of Tauri-Gum™. The Company is always mindful of the best interests of its shareholders and any utilization of this facility will be directly correlated with the creation of shareholder value or the ability to capitalize on major potential business opportunities.  The management team is excited about the Company’s future prospects and will continue to work with the greatest levels of passion and dedication.”